Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

8th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46 Annual Meeting; Oct. 25-28, 2008; Washington, D.C., USA; No. H-1269.

(3) Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results. 15th Conference on Retroviruses and Opportunistic Infections (CROI); Feb. 3-6, 2008; Boston, MA, USA; Abstract 39LB.

(4) Gulick RM, Su Z, Flexner C, et al. Phase 2 Study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis. 2007;196:304-312.

(5) Hoffmann C (2007) The epidemiology of HIV coreceptor tropism. Eur J Med Res (2007) 12: 385-390.

(6) Atazanavir sulfate is a Bristol-Myers Squibb Company prescription medicine. Please see the atazanavir product insert for information on this product.

(7) Truvada is a registered trademark of Gilead Sciences, Inc. Please see the Truvada product insert for information on this product.

(8) Data collection on adverse events of anti-HIV drugs (DAD) study group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.

(9) The DAD study group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.

(10) The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. http://www.thelancet.com published online April 2, 2008, DOI:10.1016/S0140-6736(08)60423-7.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... 12 Novartis Pharma AG has entered into an agreement ... (iloperidone), a new oral medication that is approved by the ... of adults with schizophrenia. Novartis plans to launch Fanapt ... part of the agreement with Vanda Pharmaceuticals Inc., Novartis will ...
... Conn., Oct. 12 VION PHARMACEUTICALS, INC. (OTC ... investment banking firm Merriman Curhan Ford & Co. to assist ... of a restructuring of the Company and its debt and ... may also consider financing options. , As previously reported, the ...
Cached Medicine Technology:Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 2Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 3Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 4Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 5Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 6Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 7Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 8Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives 2Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives 3
(Date:8/28/2015)... Columbus, Ohio (PRWEB) , ... August 28, 2015 ... ... Saturday’s Imagine No Malaria Day at the Zoo to celebrate children helping children, ... people and their congregations throughout West Ohio have contributed to the United Methodist ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Medical Devices:, Understanding the FDA’s Position and Best Practices for Compliance, **Presented ... , This workshop, chaired by internationally renowned expert Fubin Wu, has ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... of high grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine ... a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... of the Veterans Award, honoring military veterans leading in business. Mr. Troy ... , The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize ...
(Date:8/28/2015)... ... , ... Northridge dentists Dr. Elyson and Dr. Assili are now ... currently receive a one hour treatment of this teeth whitening option. Zoom whitening ... of unique features that can turn teeth up to nine shades whiter. Effective on ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... 45%, ATLANTA, Dec. 5 Mary Washington ... Patient Flow initiative to,dramatically improve performance. Results include ... reduction in radiology turnaround time for key emergency,procedures, ... teams working on specific parts of the ED ...
... Care for Millions of Americans, WASHINGTON, Dec. 5 ... access to medical treatment, HHS,Secretary Mike Leavitt said today ... or expand 1,200 community health centers., Health centers ... ability to pay. Charges for health care services at,health ...
... Sage Software Healthcare, Inc.,announced today that more ... Sage Practice Management system during the 2007 fiscal ... the Intergy EHR by,Sage Electronic Health Records system., ... grow, within our,customer base as well as new ...
... Navitas Cancer Rehabilitation Centers of,America, Inc. ... and,comprehensive cancer rehabilitation services, is pleased to ... located on the campus of Presbyterian/St.,Luke,s Medical ... services,agreement with Presbyterian/St. Luke,s to provide its ...
... also hit new high last year , , WEDNESDAY, Dec. 5 ... the number of teenagers having babies in the United States ... Wednesday. , That startling news was accompanied by additional data ... for unmarried women having babies as well as for Caesarean ...
... In about 20 percent of women with breast ... resonance imaging reveals important diagnostic information that alters their ... 5). , This study was presented at the 119th ... 2-5 in Hot Springs, Va., and will appear in ...
Cached Medicine News:Health News:SciHealth Inc. Helps Mary Washington Hospital Improve Emergency Department Performance 2Health News:HHS Marks Expansion of 1200th Health Center, Meeting Key Bush Goal 2Health News:Sage Software Healthcare, Inc. Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 2Health News:Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian / St. Luke's Medical Center 2Health News:Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian / St. Luke's Medical Center 3Health News:Teen Birth Rates Up for First Time in 14 Years, U.S. Reports 2Health News:Teen Birth Rates Up for First Time in 14 Years, U.S. Reports 3Health News:Breast MRI spots other cancers, may alter treatment plan 2Health News:Breast MRI spots other cancers, may alter treatment plan 3Health News:Breast MRI spots other cancers, may alter treatment plan 4
The Auto Suture™ SIGNET™ staplers place one staple each time the instrument handles are squeezed. The staples first penetrate the skin and are then formed, thus holding the tissue togethe...
The Auto Suture DFS stapler is a disposable fascia stapler. The stapler places one staple each time the instrument handles are activated. The staples first penetrate the fascia and are then formed, t...
... PROXIMATE RH skin stapler is a ... head assembly., ,PROXIMATE RH has improved ... along with a ratchet mechanism for easier ... a sterile, single patient use instrument designed ...
... two staggered rows of titanium staples in 30mm, ... up to three times for a maximum of ... for thick tissue. The TLV model fires vascular ... , Parallel jaw closure ensures that tissue is ...
Medicine Products: